AstraZeneca and Quell to Develop Cell Therapies in $2B Deal for Type 1 Diabetes and IBD

AstraZeneca has partnered with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder in a potential deal worth over $2 billion. The collaboration will involve the development of autologous multi-modular Treg cell therapies, which are designed to suppress an overactive immune response seen in organ transplantation, inflammatory and autoimmune disease. As..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 12.
  • textsms

AstraZeneca and Quell to Develop Cell Therapies for Type 1 Diabetes and IBD in $2B Deal

AstraZeneca has announced a partnership with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder. The collaboration involves the use of Quell's T-regulatory (Treg) cell engineering toolbox to develop autologous multi-modular Treg cell therapies, which will be manufactured through to the end of the first-in-human clinical study. AstraZeneca has initial..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms